Royal Bank of Canada
CLDI icon

Royal Bank of Canada’s Calidi Biotherapeutics CLDI Stock Holding History

Royal Bank of Canada’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-417
Closed -$1K – 7212
2025
Q3 		$1K Hold
417
– – ﹤0.01% 6957
2025
Q2 		$1K Hold
417
– – ﹤0.01% 6859
2025
Q1 		$3K Hold
417
– – ﹤0.01% 6472
2024
Q4 		$6K Buy
+417
New +$7.82K ﹤0.01% 6480

Other funds holding CLDI

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada's CLDI Position: Q4 2025 in Review

Royal Bank of Canada sold out of Calidi Biotherapeutics (CLDI) in Q4 2025, closing a stake of 417 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CLDI in Q4 2024 and held it in 4 quarters. The position peaked at $6K in Q4 2024. 27 funds tracked by Wall St. Rank hold CLDI as of Q4 2025.

  • Royal Bank of Canada reported no remaining Calidi Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 417 Calidi Biotherapeutics shares in Q4 2025, an estimated $1K.
  • Royal Bank of Canada first reported a position in Calidi Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • Royal Bank of Canada's Calidi Biotherapeutics position peaked at $6K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.